Neurological Complications of Cancer Treatment: Comprehensive Clinical Notes

Speaker Profiles and Context:
- Katrina Morris: A neurologist practicing at Concord Hospital and the Neurofibromatosis Clinic at North Shore.
- Institutional Affiliation: University of Sydney.
- Land Acknowledgement: Recognition of the Gadigal Wongo land and the elders who have cared for the country across the various University of Sydney campuses.
Clinical Significance:
- While brain tumors are compelling and represent critical research areas due to their devastating nature, neurological complications of general cancer treatments are significantly more common in clinical practice.
- Medical professionals across all specialties are likely to encounter these treatment-related complications more frequently than primary central nervous system (CNS) malignancies.

Nature and Occurrence:
- Neuropathy is one of the most prevalent forms of "collateral damage" resulting from oncological treatments.
- It can be dose-related (cumulative toxicity) or idiosyncratic (occurring unexpectedly after minimal exposure).
Clinical Presentation:
- Symptoms range from mild numbness and "pins and needles" (paresthesia) to a severe, length-dependent neuropathic condition.
- Impacts include pain, ataxia (loss of full control of bodily movements), and proprioceptive changes (loss of awareness of body position).
- Functional impairment is common in both upper and lower limbs, affecting daily activities and quality of life.
Etiology and Risk Factors:
- Particularly associated with platinum-based therapeutic regimes (e.g., cisplatin, oxaliplatin, carboplatin).
- Exacerbated by pre-existing nerve injury risk factors, most notably diabetes mellitus and vascular disease.
Prognosis and Management:
- Spontaneous remission of symptoms can occur following the cessation of chemotherapy.
- Symptomatic Treatment: Focused on pain management.
- Physical Therapy: Essential for maintaining function and managing ataxia/proprioception issues.
- Research Limitations: Modifying factors are under ongoing research; however, there is a clinical conflict regarding whether treating the neuropathy might inadvertently reduce the efficacy of the primary cancer treatment.

Definition and Prevalence:
- Known colloquially as "chemo brain," this refers to non-specific cognitive changes reported by patients.
- Studies indicate it affects between $20\%$ and $80\%$ of non-CNS cancer patients receiving high-dose chemotherapy.
Reported Cognitive Deficits:
- Changes in attention and concentration.
- Impairment of working memory.
- Deficits in visuospatial function.
- Chronic fatigue.
- Duration: These effects can last for protracted periods, extending long after the chemotherapy cycles have concluded.

Temporal Categories of Cognitive Change:
- Early Effects: Occurring within the first $6\text{ months}$ post-treatment.
- Late Effects: Emerging significantly later, potentially beyond $10\text{ years}$ post-cranial irradiation. This is a critical consideration for survivors of childhood brain cancers who face lifelong monitoring.
Pathological Mechanisms:
- Leukoencephalopathy: Structural changes in the white matter of the brain.
- Microbleeds: Small hemorrhages within the brain tissue.
- Synergistic Toxicity: The combined effect of radiation and chemotherapy can worsen neurological outcomes compared to either treatment alone.
Modern Mitigations:
- Hippocampal Sparing: Modern radiotherapy techniques aim to avoid the hippocampus to preserve memory function.
- Field Adjustments: Precise adjustments in the radiation field have improved cognitive outcomes over older methods.
Whole Brain Radiotherapy (WBRT):
- WBRT is essential for infiltrative brain cancers that cannot be surgically resected.
- However, its use as an upfront treatment for low-grade gliomas has become controversial due to the profound late-stage cognitive injuries it causes.

Stroke in Cancer Patients:
- Radiation-Induced: Radiation to the head, neck, or cranium can cause vascular changes and alterations in the intima (the innermost coating of blood vessels), leading to stroke.
- Cancer-Mediated: Malignancy often induces a state of hypercoagulability, predisposing patients to ischemic strokes independent of radiation.
Myopathies and Neuropathies:
- Radiation directed at a limb or the brachial plexus can cause significant localized nerve or muscle dysfunction.
- Radiation fields impacting the spinal cord can lead to permanent spinal cord changes.
- Mantle Irradiation Syndrome: A distinctive condition known as Camptocormia (involuntary forward bending of the spine) can occur up to $30\text{ years}$ after mantle irradiation for hematological malignancies (e.g., Hodgkin’s Lymphoma).

Immune Checkpoint Inhibitors (ICIs):
- A rapidly growing field of treatment expected to become central to future medical careers.
- Common Syndromes: Typically present within approximately $45\text{ days}$ of treatment initiation. Symptoms include headache, dizziness, and peripheral sensory neuropathy.
- Unusual Immune Dysregulation: Can trigger syndromes mimicking Myasthenia Gravis, Progressive Multifocal Leukoencephalopathy (PML), Multiple Sclerosis (MS), inflammatory myopathies, and inflammatory neuropathies.
Paraneoplastic Syndromes:
- Autoimmune conditions triggered by the body’s immune response to cancer.
- These syndromes appear more frequent as a "release function" in patients treated with immunotherapies.
CAR T-Cell Therapy (CD19):
- Neurotoxicity Syndrome (ICANS): A significant syndrome occurring within approximately $2\text{ weeks}$ post-infusion.
- Symptoms: Deficits in attention and language, as well as motor deficits.
- Management: Due to the commonality of these immune effector cell sequelae, patients are monitored prospectively in specialized units and treated with specific steroid protocols as necessary.